Mammary Cell News
Mammary Cell News is an online resource covering the latest research into breast cancer and mammary cells.
CREB1-BCL2 Drives Mitochondrial Resilience in RAS GAP-Dependent Breast Cancer Chemoresistance
[Oncogene] Researchers showed that RASAL2 was enriched following neoadjuvant chemotherapy in triple-negative breast cancer patients. This enrichment was specific to the tumor compartment compared to adjacent normal tissues, suggesting that RASAL2 upregulation is tumor-selective.
Triethylamine-Mediated Protonation–Deprotonation Unlocks Dual-Drug Self Assembly to Suppress Breast Cancer Progression and Metastasis
[Proceedings of The National Academy of Sciences of The United States of America] Scientists emphasized the significant clinical potential of DT as an innovative carrier-free nanomedicine and provided profound insights into the design of nanomedicines for cancer therapy.
Exosome Platform with Three-in-One Functionality of mRNA Therapy, Immune Checkpoint Blockade, and Mild Photothermal Therapy for the Treatment of Triple-Negative Breast Cancer
[ACS Applied Materials & Interfaces] Investigators presented a multifunctional nanotherapeutic platform designed to combine cytokine-sensitized mild photothermal therapy, immune checkpoint blockade (ICB), and interleukin-2 mRNA therapy to reprogram the tumor microenvironment, thereby improving the efficacy of ICB therapy in TNBC.
Genetic Advancements in Breast Cancer Treatment: A Review
[Discover Oncology] Personalized medicine, guided by genomic profiling, enhances treatment precision by identifying patient-specific mutations, such as BRCA1 and BRCA2, allowing for more tailored and effective interventions.
Kindlin-2-Mediated Hematopoiesis Remodeling Regulates Triple-Negative Breast Cancer Immune Evasion
[Molecular Cancer Research] Investigators focused on Kindlin-2, an adaptor protein, and its role in triple-negative breast cancer progression, particularly in hematopoiesis-mediated immune evasion.
Pfizer Canada and Partners Announce Quality Improvement Grant Recipients for Canada’s Most Prevalent Cancers
[Pfizer (Canada Newswire)] Pfizer Canada, together with Rethink Breast Cancer, Colorectal Cancer Canada, Lung Health Foundation, Lung Cancer Canada, and the Quebec Lung Association, announced the 2024 recipients of a series of grants to help advance oncology care and innovation in Canada.
Preclinical Evaluation of Zirconium-89 Labeled Anti-Trop2 Antibody-Drug Conjugate (Trodelvy) for Imaging in Gastric Cancer and Triple-Negative Breast Cancer
[European Journal of Nuclear Medicine and Molecular Imaging] Leveraging the enhanced specificity of antibody-drug conjugate, researchers conducted the first immunoPET imaging study of Trop2 expression in gastric cancer and TNBC models using 89Zr-labeled Trodelvy.
S100A8/A9 Innate Immune Signaling as a Distinct Mechanism Driving Progression of Smoking-Related Breast Cancers
[Oncogene] Investigators showed that S100A8/A9 innate immune signaling was a molecular mechanism that identified smoking-related breast cancers and underlied their enhanced malignancy.
The PI4K2A Gene Positively Regulates Lipid Synthesis in Bovine Mammary Epithelial Cells and Attenuates the Inhibitory Effect of t10, c12-CLA on Lipid Synthesis
[Scientific Reports] Scientists used primary bovine mammary epithelial cells (BMECs) as a model and utilized overexpression and knockdown techniques for the PI4K2A gene to investigate the specific mechanisms by which it regulated lipid metabolism in BMECs.
LINC00626 Drives Tamoxifen Resistance in Breast Cancer Cells by Interaction with UPF1
[Scientific Reports] Researchers revealed that the upregulation of LINC00626 in breast cancer was associated with poor overall survival in patients.
Omega-3 Fatty Acids: Molecular Weapons against Chemoresistance in Breast Cancer
[Cellular & Molecular Biology Letters] The authors provide an overview of the molecular mechanisms driving breast cancer chemoresistance, focusing on the role of omega-3 polyunsaturated fatty acids (ω-3 PUFAs) in recognized cellular paths and presenting current findings on the effects of ω-3 PUFAs combined with chemotherapeutic drugs in breast cancer management.
Dewpoint Therapeutics Announces DPTX3496 as a Development Candidate for the Treatment of Colorectal, Breast, and Lung Cancers
[Dewpoint Therapeutics, Inc.] Dewpoint Therapeutics, Inc. announced the nomination of a second development candidate, DPTX3496. DPTX3496 is an oral, small molecule condensate modulator targeting beta catenin to address Wnt-driven colorectal cancer, TNBC, and non-small cell lung cancer.
For over a decade, Mammary Cell News has been keeping the global scientific and medical communities informed about the latest research, reviews, and news in the field of mammary tissues. Our editors gather publications on the topic of mammary cell differentiation and characterization, as well as the progression and treatment of breast cancer. We also keep scientists up-to-date on the latest policy changes, job postings, and events.